Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Belantamab-mafodotin/Teclistamab

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kosch R, et al. Real-world experiences with detection of secondary resistance mechanisms against BCMA-targeting therapies by Whole Genome Sequencing and its association with clinical course inthMultiple Myeloma patients. Oncology Research and Treatment 46: 32 abstr. V121, Oct 2023. Available from: URL: https://dx.doi.org/10.1159/000533576 [abstract] Kosch R, et al. Real-world experiences with detection of secondary resistance mechanisms against BCMA-targeting therapies by Whole Genome Sequencing and its association with clinical course inthMultiple Myeloma patients. Oncology Research and Treatment 46: 32 abstr. V121, Oct 2023. Available from: URL: https://dx.doi.org/10.1159/000533576 [abstract]
Metadaten
Titel
Belantamab-mafodotin/Teclistamab
Lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55993-x

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Antineoplastics